Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia Sasaki JVasc Health Risk Manag 2010[Nov]; 6 (ä): 997-1005Pitavastatin was first developed in Japan and is expanding the regions in which it is clinically available. A considerable number of clinical studies have been conducted and published to date on the usefulness of pitavastatin for patients with primary hypercholesterolemia or combined dyslipidemia. Pitavastatin demonstrates potent low-density lipoprotein cholesterol reduction at low doses of 1-4 mg/day. It also affects the regression of coronary plaques, as observed in intravascular ultrasound-guided percutaneous coronary intervention studies. Moreover, the persistent, long-term high-density lipoprotein cholesterol elevation observed in the populations treated with pitavastatin is worthy of further attention. The reported improvements in lipid profiles are consistent among the studies conducted in Japan, Korea, Thailand, and Europe. In light of accumulating clinical experience worldwide, pitavastatin is now expected to establish its position for preventing and treating cardiovascular disease.|Anticholesteremic Agents/pharmacology/*therapeutic use[MESH]|Atorvastatin[MESH]|Cholesterol, HDL/drug effects[MESH]|Cholesterol, LDL/*drug effects[MESH]|Clinical Trials, Phase III as Topic[MESH]|Dyslipidemias/complications/*drug therapy[MESH]|Heptanoic Acids/pharmacology/therapeutic use[MESH]|Humans[MESH]|Hypercholesterolemia/complications/drug therapy[MESH]|Pyrroles/pharmacology/therapeutic use[MESH]|Quinolines/pharmacology/*therapeutic use[MESH]|Randomized Controlled Trials as Topic[MESH]|Treatment Outcome[MESH] |
